Rugo HS, Lerebours F, Ciruelos E, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, [...]
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Zhou et al. Lancet Respir Med. 2021 Mar;9(3):305-314. [...]
Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Suda K et al. Ann Thorac Surg. 2021 Jan;111(1):269-276.
Loibl S, Marmé F, Martin M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial. JCO 2021; JCO.20.03639.
Commentary: Lung cancer and dysbiosis: Debugging the studies for the future. Pass HI. J Thorac Cardiovasc Surg. 2021 Feb;161(2):430-431.
Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications. Amiri A et al. Curr Med Chem. 2021;28(2):308-328.
Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation. Ng TL et al. J Thorac Oncol. 2021 Mar;16(3):486-491.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Le X et al. J Thorac Oncol. 2021 Feb;16(2):205-215.
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. de Gooijer CJ, et al. Lancet Respir Med. 2021 Jan 27:S2213-2600(20)30362-3. [...]
